Johnson & Johnson Total Assets 2006-2018 | JNJ

Johnson & Johnson total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • Johnson & Johnson total assets for the quarter ending December 31, 2018 were $155.703B, a 0.03% increase year-over-year.
  • Johnson & Johnson total assets for 2017 were $157.303B, a 11.4% increase from 2016.
  • Johnson & Johnson total assets for 2016 were $141.208B, a 5.84% increase from 2015.
  • Johnson & Johnson total assets for 2015 were $133.411B, a 2.34% increase from 2014.
Johnson & Johnson Annual Total Assets
(Millions of US $)
2017 $157,303
2016 $141,208
2015 $133,411
2014 $130,358
2013 $132,683
2012 $121,347
2011 $113,644
2010 $102,908
2009 $94,682
2008 $84,912
2007 $80,954
2006 $70,556
2005 $58,864
Johnson & Johnson Quarterly Total Assets
(Millions of US $)
Q3 2018 $155,703
Q2 2018 $155,365
Q1 2018 $156,625
Q4 2017 $157,303
Q3 2017 $155,658
Q2 2017 $152,807
Q1 2017 $144,918
Q4 2016 $141,208
Q3 2016 $140,369
Q2 2016 $139,814
Q1 2016 $136,231
Q4 2015 $133,411
Q3 2015 $133,266
Q2 2015 $132,036
Q1 2015 $128,590
Q4 2014 $130,358
Q3 2014 $132,097
Q2 2014 $135,200
Q1 2014 $133,330
Q4 2013 $132,683
Q3 2013 $126,933
Q2 2013 $124,325
Q1 2013 $121,536
Q4 2012 $121,347
Q3 2012 $118,951
Q2 2012 $115,750
Q1 2012 $116,194
Q4 2011 $113,644
Q3 2011 $111,821
Q2 2011 $112,114
Q1 2011 $108,150
Q4 2010 $102,908
Q3 2010 $98,247
Q2 2010 $92,300
Q1 2010 $93,441
Q4 2009 $94,682
Q3 2009 $91,558
Q2 2009 $87,438
Q1 2009 $86,100
Q4 2008 $84,912
Q3 2008 $87,724
Q2 2008 $88,113
Q1 2008 $85,995
Q4 2007 $80,954
Q3 2007 $78,665
Q2 2007 $74,683
Q1 2007 $73,066
Q4 2006 $70,556
Q3 2006 $61,238
Q2 2006 $60,990
Q1 2006 $62,133
Q4 2005 $58,864
Q3 2005 $56,574
Q2 2005 $54,553
Q1 2005 $54,446
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $365.894B $81.581B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Pfizer (PFE) United States $252.402B 14.13
Merck (MRK) United States $215.183B 18.39
Novartis AG (NVS) Switzerland $207.623B 17.66
Eli Lilly (LLY) United States $129.746B 22.03
Novo Nordisk (NVO) Denmark $123.032B 19.90
AbbVie (ABBV) United States $121.616B 10.22
Sanofi (SNY) France $106.719B 13.17
AstraZeneca (AZN) United Kingdom $103.646B 11.83
GlaxoSmithKline (GSK) United Kingdom $102.300B 13.43
Bristol-Myers Squibb (BMY) United States $84.336B 12.98